CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 258 filers reported holding CRISPR THERAPEUTICS AG in Q1 2020. The put-call ratio across all filers is 0.73 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $715,000 | -43.1% | 11,548 | -41.9% | 0.00% | -50.0% |
| Q1 2022 | $1,257,000 | -11.7% | 19,872 | +7.2% | 0.00% | +100.0% |
| Q4 2021 | $1,423,000 | -3.2% | 18,539 | +43.0% | 0.00% | 0.0% |
| Q3 2021 | $1,470,000 | -19.2% | 12,964 | +16.4% | 0.00% | -50.0% |
| Q2 2021 | $1,820,000 | -43.5% | 11,141 | -57.9% | 0.00% | -50.0% |
| Q1 2021 | $3,223,000 | +86.7% | 26,485 | +137.0% | 0.00% | +100.0% |
| Q4 2020 | $1,726,000 | +342.6% | 11,174 | +144.4% | 0.00% | +100.0% |
| Q3 2020 | $390,000 | +93.1% | 4,572 | +66.1% | 0.00% | – |
| Q2 2020 | $202,000 | -82.0% | 2,752 | -89.8% | 0.00% | -100.0% |
| Q1 2020 | $1,121,000 | – | 26,893 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,608,874 | $160,053,562,000 | 54.44% |
| Abingworth LLP | 1,237,202 | $54,858,000 | 32.62% |
| NEA Management Company, LLC | 2,090,678 | $92,722,000 | 4.00% |
| New Leaf Venture Partners, L.L.C. | 444,708 | $19,723,000 | 3.59% |
| EcoR1 Capital, LLC | 500,000 | $22,175,000 | 2.00% |
| ARK Investment Management | 1,453,590 | $64,467,000 | 1.95% |
| CLOUGH CAPITAL PARTNERS L P | 337,731 | $14,978,000 | 1.41% |
| Casdin Capital, LLC | 220,000 | $9,757,000 | 1.19% |
| Valiant Capital Management, L.P. | 271,700 | $12,050,000 | 1.07% |
| Monashee Investment Management LLC | 110,000 | $4,879,000 | 1.03% |